Check out Dr. Dan MacArthur's assessment of the Pacific Biosciences presentation at the Advances in Genome Biology and Technology conference. Also check out Genetic Inferences take on AGBT (yes, they're really original with catchy blog names at the Sanger Institute!). In any case, a friend of mine was raving about Pacific Biosciences a few months ago, so I assumed it would blow up soon.
Categories
- Log in to post comments
More like this
I've been remiss in blogging from the Advances in Genome Biology and Technology meeting here in Marco Island, Florida, primarily due to some panic-stricken last-minute changes to the slides for my own presentation last night.
Fortunately the conference has been extremely well-covered by others:…
More huge news in the sequencing industry, following on from the public share offer from Pacific Biosciences - relative newcomer to the field, Ion Torrent, has just been bought by Life Technologies for an impressive US$375 million in cash and stock, with an option to increase by a further US$350…
I'll be at the Advances in Genome Biology and Technology meeting next week - this will be my my first experience of this annual conference on Florida's picturesque Marco Island, but I already have high expectations based on reports from previous years. The programme is packed with cutting-edge…
Dan Koboldt has a very nice recap of the various sequencing technologies presented at last week's Advances in Genome Biology and Technology meeting. I totally agree with his central point:
Something had been bothering me about the sequencing-company presentations this year, and I finally realized…
"Many interesting critters have had this treatment, including bonobo, panda and Desmond Tutu (in order of majesty)."
Bloody British blog - he doesn't say whether that's ascending order or descending order.
As a bio-noob, I've often wondered what the fuss is about. Are we just talking about a machine that can economically sequence a whole human genome here?
Presumably the killer app of such technology is to sequence a large number of people and get a statistical version of the genotype-phenotype mapping, so that we can know what treatments, etc will work on a person because we know what worked on other individuals with similar DNA sequences. Or am I missing something here?